<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Impaired <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is now recognized to be central to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="1" pm="."><plain>Bcl2, activated by chromosomal translocation in human follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, promotes <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> by inhibiting <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="33173">Bim</z:chebi>, a distant proapoptotic relative, is emerging as a major physiologic <z:chebi fb="68" ids="48706">antagonist</z:chebi> of Bcl2 </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we show that loss of <z:chebi fb="3" ids="33173">Bim</z:chebi> is oncogenic </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="3" ids="33173">Bim</z:chebi> protein levels were elevated in the <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-prone B lymphoid cells of Emicro-Myc-transgenic mice, and <z:chebi fb="3" ids="33173">Bim</z:chebi>-mutant Emicro-Myc mice had increased numbers of IgM-bearing B cells </plain></SENT>
<SENT sid="5" pm="."><plain>Emicro-Myc-expressing B lymphoid cells deficient in <z:chebi fb="3" ids="33173">Bim</z:chebi> were refractory to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced in vitro by cytokine deprivation or antigen receptor cross-linking </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, <z:chebi fb="3" ids="33173">Bim</z:chebi> is induced by Myc in B cells and mediates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Remarkably, inactivation of even a single allele of <z:chebi fb="3" ids="33173">Bim</z:chebi> accelerated Myc-induced development of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, particularly <z:hpo ids='HP_0011009'>acute</z:hpo> B cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>None of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> from <z:chebi fb="3" ids="33173">Bim</z:chebi>(+/-) Emicro-Myc mice displayed loss of the second allele of <z:chebi fb="3" ids="33173">Bim</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>These findings indicate that <z:chebi fb="3" ids="33173">Bim</z:chebi> is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor, at least in B lymphocytes, and is haploinsufficient </plain></SENT>
<SENT sid="10" pm="."><plain>Whereas the p19Arf/p53 pathway is frequently mutated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> arising in <z:chebi fb="3" ids="33173">Bim</z:chebi>(+/+) Emicro-Myc mice, it was unaffected in most <z:chebi fb="3" ids="33173">Bim</z:chebi>-deficient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, indicating that <z:chebi fb="3" ids="33173">Bim</z:chebi> reduction is an effective alternative to loss of p53 function </plain></SENT>
</text></document>